{"id":48578,"date":"2022-09-20T14:01:55","date_gmt":"2022-09-20T12:01:55","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/"},"modified":"2022-09-20T14:01:55","modified_gmt":"2022-09-20T12:01:55","slug":"maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/","title":{"rendered":"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives"},"content":{"rendered":"
\n

\nIndustry-leading talent joins leadership team as company accelerates its CLAROMER\u2122 drug platform<\/i>\n<\/p>\n

\nTony Verco, MD, MBA, appointed Chief Medical Officer<\/i>\n<\/p>\n

\nBeth Burnside, PhD, appointed Senior Vice President of Research and Development Strategy<\/i>\n<\/p>\n

\nDonald Treacy, Jr., PhD, appointed Senior Vice President, Development Operations<\/i>\n<\/p>\n

AUSTIN, Texas–(BUSINESS WIRE)–Maxwell Biosciences (\u201cMaxwell”), a preclinical drug platform company focused on the development of synthetic compounds that mimic biomolecules known as biomimetic therapeutics, today announced the appointments of three senior executives: Tony Verco, MD, MBA, as Chief Medical Officer; Beth Burnside, PhD, as Senior Vice President of Research and Development (R&D) Strategy; and Donald Treacy, Jr., PhD, as Senior Vice President, Development Operations. The appointments further strengthen Maxwell\u2019s management team, bringing industry-leading leadership to support the company\u2019s clinical R&D strategy and operations.\n<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cAs Maxwell looks to accelerate the progress of its CLAROMER<\/i>\u2122 drug platform, we are pleased to welcome Tony, Beth, and Don,\u201d said Maxwell Biosciences CEO and Co-Founder, Joshua McClure. \u201cI am confident that the appointments of these industry veterans \u2013 who bring extensive depth and breadth of expertise \u2013 will further strengthen our world-class team and position us to more rapidly realize the benefits of our platform, offering a new approach to safely and effectively inactivate viruses, bacteria and fungi to benefit patients across a variety of infections.\u201d\n<\/p>\n

\nTony Verco, MD, MBA has over 25 years of international biotech and pharmaceutical experience, with a specific focus on early-stage drug development, operational oversight, and pharmacovigilance of clinical trial programs. He most recently was the owner of Shelton Clinical Research Consultants, LLC, and previously held leadership roles at Medwell Capital Corp. (formerly BioMS Medical Corp.), Endpoint Research and AstraZeneca, UK. He also held Unit Physician and Principal Investigator roles at AstraZeneca, UK, and Leicester Clinical Research Center. He holds a Bachelor of Medicine, Bachelor of Surgery (MD) from the University of the Witwatersrand in South Africa, a Masters in Business Administration (MBA) from New York Institute of Technology in the U.S., and a Diploma in Anaesthetics (DA) from the Royal College of Medicine in South Africa.\n<\/p>\n

\nOver the past 30 years, Beth Burnside, PhD, has led teams across drug development and delivery, enhanced drug absorption, regulatory affairs, quality and corporate compliance, and intellectual property strategy. She has served as lead inventor or co-inventor on more than 34 issued U.S. patents and numerous related international patents, including developing several pharmaceutical products such as Adderall XR\u00ae<\/sup>, Intuniv\u00ae<\/sup>, and MOXATAG\u00ae<\/sup>. Prior to joining Maxwell, she held executive roles with Lowery Creek Consulting, LLC, QRxPharma, MiddleBrook Pharmaceuticals, Inc. (formerly Advancis Corporation), and Shire Pharmaceuticals. She holds a PhD in Physical Organic Chemistry and an MS in Organic Chemistry, both from Drexel University, and a BS in Chemistry and Mathematics from Muhlenberg College.\n<\/p>\n

\nDonald Treacy, Jr., PhD, brings 30 years of experience across the biotech and pharmaceutical industry, with diverse expertise across research, product development and manufacturing, and regulatory affairs. He most recently was the CEO of Magothy Consulting Group, LLC, and previously held the role of Senior Vice President of Development and Manufacturing Operations at MiddleBrook Pharmaceuticals, Inc. (formerly Advancis Corporation), and Senior Director of Analytical Sciences at Shire Pharmaceuticals. He is the named inventor on over 30 issued U.S. and international patents in novel drug delivery, solid dosage form development and formulation performance, and has authored numerous research publications and presentations on accelerator mass spectrometry, high performance liquid chromatography, and novel drug delivery systems. He holds a PhD in Analytical and Nuclear Chemistry from the University of Maryland, and a BA in Chemistry from Roanoke College.\n<\/p>\n

\nAbout Maxwell<\/b>\n<\/p>\n

\nFounded in 2016, Maxwell Biosciences is a preclinical drug platform company which develops biomimetic therapeutics \u2013 synthetic compounds that mimic and improve upon biomolecules. Inspired by nature, these low-molecular weight compounds are created by Maxwell\u2019s exclusive first-in-class, CLAROMER\u2122 brand drug platform and have been shown to be effective in destroying viruses, bacteria, fungi and some cancers, while safely avoiding healthy cells. These drug candidates have been shown to be well-tolerated in human tissues in vitro, and in animal studies. The compounds imitate key components of the immune system, humanity\u2019s greatest asset in fighting disease. Maxwell\u2019s technology is protected by granted patents and is led by a world-class team of experienced life science executives. To learn more about Maxwell Biosciences, visit MaxwellBiosciences.com<\/a>, or follow us on Twitter<\/a> and LinkedIn<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia:<\/i>
Edelman Smithfield for Maxwell Biosciences, Inc.
\n
MaxwellBiosciences@edelman.com<\/a>\n<\/p>\n

\nInvestors:<\/i>
Mira Sirotic, CMA
\n
investor.relations@maxwellbiosciences.com<\/a>
Maxwell Biosciences, Inc.\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Industry-leading talent joins leadership team as company accelerates its CLAROMER\u2122 drug platform Tony Verco, MD, MBA, appointed Chief Medical Officer Beth Burnside, PhD, appointed Senior Vice President of Research and Development Strategy Donald Treacy, Jr., PhD, appointed Senior Vice President, Development Operations AUSTIN, Texas–(BUSINESS WIRE)–Maxwell Biosciences (\u201cMaxwell”), a preclinical drug platform company focused on the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-48578","6":"format-standard","7":"category-industry"},"yoast_head":"\nMaxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Industry-leading talent joins leadership team as company accelerates its CLAROMER\u2122 drug platform Tony Verco, MD, MBA, appointed Chief Medical Officer Beth Burnside, PhD, appointed Senior Vice President of Research and Development Strategy Donald Treacy, Jr., PhD, appointed Senior Vice President, Development Operations AUSTIN, Texas–(BUSINESS WIRE)–Maxwell Biosciences (\u201cMaxwell”), a preclinical drug platform company focused on the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-20T12:01:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220919005886\/en\/1576807\/21\/Beth_Burnside_Headshot.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives\",\"datePublished\":\"2022-09-20T12:01:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/\"},\"wordCount\":756,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005886\\\/en\\\/1576807\\\/21\\\/Beth_Burnside_Headshot.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/\",\"name\":\"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005886\\\/en\\\/1576807\\\/21\\\/Beth_Burnside_Headshot.jpg\",\"datePublished\":\"2022-09-20T12:01:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005886\\\/en\\\/1576807\\\/21\\\/Beth_Burnside_Headshot.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220919005886\\\/en\\\/1576807\\\/21\\\/Beth_Burnside_Headshot.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/","og_locale":"en_US","og_type":"article","og_title":"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives - Pharma Trend","og_description":"Industry-leading talent joins leadership team as company accelerates its CLAROMER\u2122 drug platform Tony Verco, MD, MBA, appointed Chief Medical Officer Beth Burnside, PhD, appointed Senior Vice President of Research and Development Strategy Donald Treacy, Jr., PhD, appointed Senior Vice President, Development Operations AUSTIN, Texas–(BUSINESS WIRE)–Maxwell Biosciences (\u201cMaxwell”), a preclinical drug platform company focused on the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-20T12:01:55+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220919005886\/en\/1576807\/21\/Beth_Burnside_Headshot.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives","datePublished":"2022-09-20T12:01:55+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/"},"wordCount":756,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220919005886\/en\/1576807\/21\/Beth_Burnside_Headshot.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/","url":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/","name":"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220919005886\/en\/1576807\/21\/Beth_Burnside_Headshot.jpg","datePublished":"2022-09-20T12:01:55+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220919005886\/en\/1576807\/21\/Beth_Burnside_Headshot.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220919005886\/en\/1576807\/21\/Beth_Burnside_Headshot.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/maxwell-biosciences-expands-leadership-team-with-the-appointment-of-three-senior-executives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Maxwell Biosciences Expands Leadership Team with the Appointment of Three Senior Executives"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=48578"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/48578\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=48578"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=48578"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=48578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}